Skip to content
thestock.space

Evexia Lifecare (BSE: EVEXIA) had a P/E of 146.0× on 6 Nov 2026, above the industry P/E of 36.7×, and the shares are 36% below their 52-week high. It earns ROCE of 0.3% and ROE of 0.3%, and sales and net profit grew 17% and 34% a year over 3 years. Debt is 0.69× equity. It is a small-cap company with a market cap of ₹274 Cr, ranked 4th of 11 Medical Distribution companies by market cap; the shares fell 15% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹1.53
Day high
₹1.53
Day low
₹1.44
Prev. close
₹1.51
Volume
50.6 L

Health check

1 fair · 5 to check
  • ReturnsBehind

    −15.2% over a year, better than 2 of 7 peers.

  • Price tagPricier

    P/E 146.0 vs industry 36.7.

  • GrowthSlow

    Sales +16.6%, profit +34.5% a year over 3 years.

  • ProfitabilityWeak

    ROCE 0.3% vs peer median 9.4%.

  • Balance sheetFair

    Debt 0.69× equity, interest covered 315.1×, Piotroski 6 of 9.

  • Red flags5 to check

    Return on equity is low at 0.3%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Medical Distribution

10 listed peers. Screen the industry

Small cap

₹274 Cr, #4 of 11 in its industry by size.

High beta

Beta 1.45 vs the NIFTY 50: swings more than the market.

Key metrics

Last 12 months to Sep 2026: sales ₹113 Cr · profit ₹1 Cr
Market cap
₹274 Cr
Small cap
P/E
146.0
Industry 36.7
Price to book
0.67
Peers 2.10
Dividend yield
0.00%
ROE
0.3%
Peers 8.0%
ROCE
0.3%
Peers 9.4%
Debt to equity
0.69
Debt ₹332 Cr
EPS (TTM)
₹0.01
OPM (TTM)
1.6%
Net margin 1.0%
Sales growth
−2.8%
Latest quarter vs a year ago
Profit growth
−37.9%
Latest quarter vs a year ago
Price to sales
2.43
EV/EBITDA 134.4

Strengths and risks

Risks to check

  • Return on equity is low at 0.3%.
  • Quarterly profit down 37.9% on a year ago.
  • Quarterly sales down 2.8% on a year ago.
  • P/E of 146.0 against an industry P/E of 36.7.
  • 36% below its 52-week high.

No standout strengths in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Evexia Lifecare

Evexia Lifecare Limited, together with its subsidiaries, engages in the trading of pharmaceutical chemicals in India. The company also offers personalized healthcare solutions; and diagnostic solutions, such as early detection, diagnosis, and monitoring of health conditions. In addition, it is involved in the manufacturing of plastic granules. The company was formerly known as Kavit Industries Limited and changed its name to Evexia Lifecare Limited in…

Headquarters
Vadodara
Employees
9
Sector
Healthcare
ISIN
INE313M01030
Website
evexialifecare.com

Price range

52 weeks

₹0.47₹2.28

Today

₹1.44₹1.53
Avg volume (3M)
1.6 Cr
1-year return
minus 15.2%
From 52-week high
minus 36.0%

Peers · Medical Distribution

Compare with peersScreen the whole industry
Company
ENTEROEntero Healthcare Solutions1,900.40plus 8.34%8,27966.04.9011.3%6.7%4.4%25.7%–0.00%plus 62.4%
APPLAptus Pharma465.00plus 0.92%797100.228.0629.3%31.7%15.4%49.6%187.5%0.00%plus 772.6%
ARVAYAArvaya Healthcare111.00minus 4.31%576––1.4%2.2%0.0%193.6%–0.00%plus 143.1%
EVEXIAEvexia Lifecare1.46minus 3.31%274146.00.670.3%0.3%1.6%16.6%34.5%0.00%minus 15.2%
NOVELIXNovelix Pharmaceuticals64.66minus 4.91%18436.72.937.4%8.0%3.1%354.8%–0.00%plus 29.5%
AMWILLAmwill Health Care44.00plus 5.67%887.81.0615.5%14.4%14.1%14.7%54.2%2.27%minus 25.4%
CBPLChandra Bhagat Pharma55.50minus 4.31%4213.71.26–9.7%2.5%––0.00%plus 45.0%
WELCUREWelcure Drugs and Pharmaceuticals0.18minus 5.26%22–0.23−5.7%−5.5%−1.5%––0.00%minus 62.7%
Median of 7 peers–−4.31%18436.72.109.4%8.0%3.1%49.6%120.8%0.00%45.0%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrSep 25Dec 25Mar 26Jun 26Sep 26
25.725.236.830.925
25.62535.730.425.1
0.10.31.10.5−0.1
0.4%1.0%3.0%1.7%−0.3%
0.40.30.10.20.8
00000.1
00.10.30.10.3
0.50.40.90.60.4
26.8%26.0%13.3%25.8%36.7%
0.40.30.80.40.2
0.00–0.000.000.00

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+16.6%
Profit CAGR 3Y
+34.5%
EPS CAGR 3Y
−7.2%
ROE
0.3%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
69.654.986.6110
–minus 21.0%+57.7%+27.4%
68.953.785107
0.61.21.62.9
0.9%2.2%1.9%2.6%
1.30.90.1−0
0.50.40.40
0.40.40.50.7
0.50.6––
1.51.90.92.2
56.4%28.6%55.1%26.3%
0.71.40.41.6
–+106.9%minus 70.1%+293.0%
0.010.020.000.01

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
66.470.8188188
2458.6272247
7056863752.9
52.267.360434
848883894871
1110.810.618
000–
0.972410.9711
0.50.80.62.8
835148872140
848883894871

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
−3.117−4.4−23.5
−697−17.3−15.852.7
6990.620.1−27.7
−1.10.3−0.11.5
−2.4−0.3−34.5−3.2
−5.616.8−4.4−26.7

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders. Institutions hold about 15.4% (Yahoo estimate).

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you